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Abstract
Adenosine deaminases acting on RNA (ADARs) convert adenosine to inosine in double-stranded RNA. A-to-I editing of
RNA is a widespread posttranscriptional process that has recently emerged as an important mechanism in cancer biology.
A-to-I editing levels are high in several human cancers, including thyroid cancer, but ADAR1 editase-dependent
mechanisms governing thyroid cancer progression are unexplored. To address the importance of RNA A-to-I editing in
thyroid cancer, we examined the role of ADAR1. Loss-of-function analysis showed that ADAR1 suppression profoundly
repressed proliferation, invasion, and migration in thyroid tumor cell models. These observations were validated in an
in vivo xenograft model, which showed that ADAR1-silenced cells had a diminished ability to form tumors. RNA editing of
miRNAs has the potential to markedly alter target recognition. According to TCGA data, the tumor suppressor miR-200b is
overedited in thyroid tumors, and its levels of editing correlate with a worse progression-free survival and disease stage. We
confirmed miR-200b overediting in thyroid tumors and we showed that edited miR-200b has weakened activity against its
target gene ZEB1 in thyroid cancer cells, likely explaining the reduced aggressiveness of ADAR1-silenced cells. We also
found that RAS, but not BRAF, modulates ADAR1 levels, an effect mediated predominantly by PI3K and in part by MAPK.
Lastly, pharmacological inhibition of ADAR1 activity with the editing inhibitor 8-azaadenosine reduced cancer cell
aggressiveness. Overall, our data implicate ADAR1-mediated A-to-I editing as an important pathway in thyroid cancer
progression, and highlight RNA editing as a potential therapeutic target in thyroid cancer.
Introduction
Mutations in DNA are not the only source of modifications
to the genomic content of human cells. RNA editing is a
widespread posttranscriptional mechanism to engender
genomic diversity by specifically and reproducibly
changing selected RNA sequences without altering the
genomic blueprint [1, 2]. The conversion of adenosine to
inosine (A-to-I editing) is considered the most common
RNA modification in mammals, with millions of editing
sites detected thus far in humans [2, 3]. RNA editing is
catalyzed by the adenosine deaminase acting on RNA
(ADAR) family of enzymes in double-stranded RNA of
more than 20 bp in length [4], formed both intra- and
intermolecularly [5]. Among the three types of known
mammalian ADARs, ADAR1 is the most prevalent and is
expressed ubiquitously [6]. Transcription from independent
promoters generates two isoforms of ADAR1—a full length
interferon-inducible ADAR1 p150 transcript, and a shorter
and constitutively expressed ADAR1 p110 form [7].
As a result of RNA editing, inosines are interpreted by
the cellular machinery as guanosines, and are base-paired
with cytosine, making the effect of A-to-I editing similar to
an A-to-G substitution [5]. Accordingly, editing of coding
mRNAs may lead to the creation of stop codons, or to
changes in splice sites or missense codons that give rise to
recoding, creating structurally and functionally unique
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isoforms of proteins from the same transcript. The majority
of editing activity in human cells, however, occurs in
repetitive element regions and noncoding sequences, mod-
ifying regulatory RNAs and their binding sites [1, 3, 5].
Some microRNA (miRNA) precursors undergo A-to-I
editing, which regulates the expression and/or function of
mature miRNAs. miRNAs are short noncoding RNAs that
function posttranscriptionally to suppress gene expression
through interactions of their seed region with com-
plementary sequences in the 3′-untranslated regions (UTRs)
of target messenger RNAs [8], and their misregulation can
lead to human diseases such as cancer [8–12]. In some
contexts, editing of a primary miRNA can affect its bio-
genesis, inhibiting miRNA maturation. Alternatively, it can
alter the recognition of the target mRNA, particularly if
editing occurs within the seed sequence of the miRNA [7].
Thus, A-to-I alterations result in dynamic RNA muta-
tions, which could ultimately lead to cancer outcomes
similar to those caused by genomic mutations, but with
higher flexibility as they affect only a fraction of the tran-
scripts. Aberrant RNA editing is an underexplored
mechanism that can reproducibly alter protein and reg-
ulatory RNA sequences, acting as a driver of carcinogen-
esis, and therefore, a potential therapeutic target [13].
Indeed, A-to-I editing and the enzymes mediating this
modification are significantly altered in cancer. In most
tumor types, editing levels are elevated when compared
with matched normal tissues, with the strongest levels
reported in breast, thyroid, and head and neck cancers
[13, 14]. By contrast, a significant number of RNA editing
sites are underedited in kidney chromophobe and kidney
papillary cell carcinoma tumors, among others [13, 15].
According to data from The Cancer Genome Atlas
(TCGA), thyroid cancer shows high levels of editing when
compared with matched normal tissue [13, 14], and should
thus provide a good model to study the RNA editing pro-
cess. Furthermore, although the mRNA expression of
ADAR1 may not directly reflect the editing activity [13, 16],
its expression is low in thyroid carcinomas but is sig-
nificantly elevated over normal tissue [13, 14], and high
ADAR1 mRNA expression correlates with worse
progression-free survival [13]. Thyroid cancer is the most
frequent endocrine malignancy and is the most rapidly
increasing of all cancers in the United States [17]. Thyroid
cancer generally has a good outcome [18], and thyr-
oidectomy with radioiodine ablation and thyroid-
stimulating hormone suppressive therapy remains the cor-
nerstone of treatment for patients with thyroid cancer,
although it is often not curative. Indeed, some patients
develop aggressive forms of the disease that are untreatable
and the molecular bases are poorly understood [18].
Accordingly, a better understanding of thyroid cancer is
essential for the development of new effective therapies.
The classical view of thyroid cancer pathogenesis considers
thyroid carcinomas as tumors accumulating mutations that
drive progression through a dedifferentiation process, giv-
ing rise initially to well-differentiated carcinomas such as
papillary (PTC) and follicular (FTC), and progressing to
poorly differentiated (PDTC) and undifferentiated or ana-
plastic (ATC) thyroid carcinoma [18]. Recently, a mole-
cular classification of thyroid carcinomas based on
mutations in the main known signaling pathways, MAPK,
and PI3K, has been established. Further, two genetic types
of carcinomas have been defined based on the manner in
which the oncogenes BRAF and RAS promote tumor
initiation and progression, and their relationship to the main
pathways [19]. BRAF-driven tumors have high MAPK
activity, whereas RAS-driven tumors largely show a
hyperactivation of the PI3K pathway [20, 21]. Nevertheless,
to date no studies have addressed the relationship between
ADAR1-dependent A-to-I editing and the main oncogenic
pathways and driver mutations in thyroid cancer.
Here, we establish, for the first time to our knowledge,
the functional consequences of A-to-I editing in thyroid
cancer cells. We show that ADAR1 expression and con-
sequent RNA editing alters thyroid cancer cell aggressive-
ness through its effects on proliferation, invasion,
migration, and 3D growth in vitro, and tumor growth
in vivo. We explored the molecular mechanisms underlying
these effects, finding that the tumor suppressor miR-200b is
overedited in thyroid tumors, and that RNA editing impairs
its ability to inhibit the epithelial–mesenchymal transition
(EMT) marker ZEB1. Finally, we relate the main thyroid
cancer signaling pathways to ADAR1 isoform levels, and
we provide evidence that pharmacological inhibition of A-
to-I editing in thyroid cancer cells diminishes aggressive-
ness in vitro, highlighting RNA editing as an exciting
subject for research into thyroid cancer mechanisms and
treatment options.
Results
ADAR1 silencing diminishes thyroid cancer cell
aggressiveness in vitro and in vivo
ADAR1 expression is slightly higher in thyroid tumors than
in matched normal samples [13–15]. However, according to
TCGA data (https://portal.gdc.cancer.gov/), more robust
differences are found in the levels of RNA editing, with
thyroid tumors showing one of the highest overediting
levels when compared with matched normal tissue [13–15].
Thyroid tumor cells thus provide a novel model to study the
effect of A-to-I editing. To test the importance of ADAR1
in thyroid cancer, we performed ADAR1 loss-of-function
assays in three thyroid cancer cell lines: a PTC cell line
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(TPC1) and two ATC cell lines (Cal62 and 8505c). We used
two different siRNAs targeting ADAR1, finding that both
markedly decreased ADAR1 mRNA levels (Fig. S1a),
which was accompanied by a corresponding loss in A-to-I
editing activity (Fig. S1b). ADAR1 silencing profoundly
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MTT reduction and crystal violet staining, and decreased
the levels of the proliferation marker PCNA (Fig. 1a–c). We
confirmed these observations using a three-dimensional
(3D) model, which better mimics the complexity and het-
erogeneity of tumors [22]. ADAR1 knockdown reduced the
growth of TPC1 and Cal62 cells in 3D Matrigel cultures
(Fig. 1d). Of note, we observed that in contrast to control
cells, which invaded the 3D Matrigel substrate and ulti-
mately attached to the bottom of the plate, silenced cells
were unable to invade and remained as spheres over time
(Fig. 1d). As expected, quantification of invasion (Fig. 2a)
and migration (Fig. 2b) capacity revealed a marked decrease
in both parameters in all ADAR1-silenced cells as compared
with control cells.
We next used a heterotopic xenograft model utilizing
luciferase-expressing Cal62-Luc cells to question whether
the repression of ADAR1 expression in aggressive thyroid
cells affects tumor growth in vivo. As anticipated, tumor
growth was significantly delayed in the ADAR1-silenced
group (Fig. 2c, d and Fig. S2a, b). No differences were
noted between the weight of the mice injected with ADAR1-
silenced or control cells, suggesting no adverse effects of
the silenced cells (Fig. S2c).
ADAR1 silencing reduces ZEB1 levels by abolishing
editing of miR-200b
Given that ADAR1 silencing suppresses thyroid cancer cell
aggressiveness, we next examined the effects of ADAR1
silencing on EMT, a cancer hallmark involved in thyroid
cancer progression. We tested the expression of several
EMT regulators (not shown) and found that ZEB1 (zinc
finger E-box-binding homeobox 1) was the most dysregu-
lated upon ADAR1 silencing (Fig. 3a). ZEB1 is a critical
activator of EMT in thyroid [23, 24] and other cancer [25–
29] types. Silencing of ADAR1 led to a corresponding
decrease in the abundance of ZEB1 in both TPC1 and Cal62
cells (Fig. 3a). ZEB1 is regulated in different tissues by
miR-200b-3p [30–32], which directly targets the ZEB1 3′
UTR and reduces its expression. Accordingly, miR-200b
has been described as a tumor suppressor miRNA that
disrupts EMT programs [33, 34], and it is under intensive
clinical investigation as a promising therapeutic cancer
target [35]. Although relatively little is known about miR-
200b in thyroid cancer, it is downregulated in ATC, the
most aggressive form of the disease [36, 37]. It has been
recently reported that a recurrent editing site occurs in the
seed region of miR-200b-3p in multiple cancers in TCGA
cohort, including thyroid cancer where miR-200b is con-
siderably overedited [38]. Of note, the editing hotspot in
miR-200b is significantly associated with disease stage, and
a worse progression-free survival [38]. We validated miR-
200b overediting in six thyroid tumors and their con-
tralateral normal tissue (clinical characteristics are sum-
marized in Table S1) by qRT-PCR, confirming that the
miR-200b edited/wild-type (WT) ratio is significantly
increased in tumor samples (Fig. 3b).
To test whether abnormal expression of ADAR1 in
thyroid cancer cell lines affects miR-200b editing, we
analyzed the miR-200b edited/WT ratio in ADAR1-silenced
TPC1 and Cal62 cells, and found that the editing ratio
decreased (Fig. 3c). This result indicates that ADAR1
contributes to miR-200b editing, and points to its partici-
pation in miR-200b editing in tumor thyroid cells. To
question whether the decrease in ZEB1 expression in
ADAR1-silenced cells was due to miR-200b-mediated
repression, we performed luciferase reporter assays in
control and ADAR1-silenced cells to test the ZEB1 3′UTRs
containing a WT or a mutated (negative control) miR-200b
binding sites. The Renilla/Firefly ratio was reduced in
ADAR1-silenced cells with WT ZEB1 3′UTR, confirming
that the decrease in ZEB1 expression was mediated through
its 3′UTR. By contrast, the Renilla/Firefly ratio was
unchanged when expressed from the mutated form of the 3′
UTR (Fig. 3d), supporting that loss of ZEB1 expression was
due to the miR-200b binding sites within its 3′UTR.
Because the editing hotspot in miR-200b is located in its
seed region [38], we hypothesized that the under-editing of
miR-200b provoked by ADAR1 silencing would lead to
high levels of WT miR-200b, which has a higher affinity for
the ZEB1 3′UTR, leading to the suppression of ZEB1
expression. To test this, we assessed the activity of WT and
edited miR-200b on the ZEB1 3′UTR, and their ability to
inhibit ZEB1 expression, and hence invasion capacity, in
thyroid cancer cells.
We found that WT miR-200b directly represses ZEB1
through its 3′UTR in TPC1 and Cal62 thyroid cancer cells,
as its overexpression significantly decreased the activity of a
co-transfected luciferase reporter construct containing the
putative miR-200b binding region in the ZEB1 3′UTR.
Conversely, nonsignificant changes in luciferase activity
were observed when the ZEB1 3′UTR construct was
mutated in the predicted binding sites for miR-200b
(Fig. 3e). When we repeated the assays with the edited
Fig. 1 ADAR1 knockdown reduces thyroid cancer cells prolifera-
tion and 3D growth. TPC1, Cal62, and 8505c cell lines were
transfected with two different siRNAs against ADAR1 (siADAR1
#1 and siADAR1 #2) or a control siRNA (siControl). a MTT assay
at the indicated time points. b Upper panel: representative images of
crystal violet-stained colonies. Bottom panel: quantification of crystal
violet absorbance. c Immunoblot of ADAR1 and proliferating cell
nuclear antigen (PCNA) at 72 and 96 h after transfection. GAPDH was
used as a loading control. d 3D cell culture. Values represent mean ±
SD (n= 3). Asterisks represents significant difference between siA-
DAR1 #1 and siControl, and Hash represents significant difference
between siADAR #2 the siControl. */#p < 0.05; **/##p < 0.01;
***/###p < 0.001.
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miR-200b mimic, we found a significant decrease in its
ability to repress luciferase activity through the ZEB1 3′
UTR in TPC1 and Cal62 cell lines (Fig. 3e).
We performed western blotting to confirm these data.
Accordingly, ZEB1 protein expression was markedly lower in
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mimic than in control cells, whereas transfection with the
edited miR-200b mimic resulted in an intermediate level of
ZEB1 (Fig. 4a). Interestingly, miR-200b (WT or the edited
form) do not affect ADAR1 protein expression levels
(Fig. 4a). Finally, as the miR-200b-ZEB1 axis is mainly
involved in EMT and invasion, we performed Matrigel inva-
sion assays in control and ADAR1-silenced Cal62 cells over-
expressing the WT or edited miR-200b. As expected,
expression of WT miR-200b decreased invasion in control and
ADAR1-silenced cells, whereas expression of edited miR-
200b had no effect (Fig. 4b), likely due to its reduced capacity
to inhibit ZEB1.
ADAR1 regulation in thyroid cancer cells is PI3K-
dependent
We next focused on the regulation of ADAR1 in thyroid
cancer. As mentioned earlier, PI3K and MAPK are the two
main signaling pathways involved in thyroid cancer devel-
opment and progression [19–21]. To block these pathways in
tumor cells, we used the inhibitors AKTi and selumetinib, or
their combination. Assays were performed in TPC1 cells,
which are mutated in RET/PTC, and in Cal62 cells, which are
mutant for KRAS. Inhibition of the PI3K pathway significantly
decreased the expression of the ADAR1 p150 isoform in both
cell lines (Fig. 5a). In addition, although selumetinib alone had
no effect on ADAR1 expression, the combination of both
inhibitors inhibited both ADAR1 isoforms (Fig. 5a).
We next investigated whether ADAR1 expression is
altered during the earliest steps of thyroid tumorigenesis dri-
ven by RAS and BRAF, the two main oncogenes in thyroid
cancer [19]. To do this, we used rat thyroid-derived PCCl3
cells conditionally expressing HRASV12 (PCCl3-HRAS) or
BRAFV600E (PCCl3-BRAF) upon addition of doxycycline.
Doxycycline treatment for 48 and 72 h increased ADAR1
p150 isoform levels in PCCl3-HRAS cells (Fig. 5b) but not in
PC-BRAF cells (Fig. 5c), indicating that HRAS, but likely
not BRAF, induces ADAR1 p150 expression. By contrast, no
changes were detected in the levels of the ADAR1 p110
isoform upon activation of RAS or BRAF.
8-azaadenosine blocks RNA editing and inhibits
proliferation, 3D growth, invasion, and migration in
thyroid cancer cells
Our results thus far implicate ADAR1-mediated A-to-I editing
in thyroid cancer progression, suggesting that the repression of
this process might be therapeutically useful. To test this, we
used 8-azaadenosine (8-aza) as an A-to-I editing inhibitor, in
TPC1 and Cal62 cells. Consistent with its activity against other
tumor types [39], 8-aza inhibited the editing activity of both
cell lines at a concentration of 1 and 2 µM, which were optimal
in our model (Fig. 6a). By contrast, ADAR1 mRNA levels
remained stable in both cells lines (Fig. 6b), demonstrating that
8-aza targets ADAR activity only. Mirroring the effects of
ADAR1 silencing, 8-aza decreased cell viability/proliferation in
a dose-dependent manner, as measured by MTT reduction and
crystal violet staining (Fig. 6c, d). To better assess cell growth,
we used the 3DMatrigel model, and confirmed that cell growth
was impaired in the presence of different concentrations of 8-
aza (Fig. 7a). Lastly, 8-aza impeded invasion (Fig. 7b) and
migration (Fig. 7c) of TPC1 and Cal62 cells. Overall, our data
highlight the A-to-I RNA editing pathway as an important
mechanism for thyroid cancer progression and a possible new
target for thyroid cancer therapy.
Discussion
A better understanding of new mechanisms in tumorigen-
esis is crucial to develop treatment strategies for cancer
therapy. RNA editing is frequently upregulated in cancer,
and has the capacity to impact RNA stability and splicing,
protein sequence, and miRNA–target interactions. One of
the most studied RNA editing phenomena is the conversion
of adenosine to inosine involving the RNA editing enzyme
ADAR1 [40–42]. Indeed, ADAR1-mediated RNA editing
has emerged as a dominant driver of cancer relapse and
progression [43–45], and ADAR1 is a demonstrated onco-
gene in other tumor types, including oral cancer [46], cer-
vical cancer HeLa cells [47], lung cancer [48], and
esophageal squamous cell carcinoma [45]. However, the
functional impact of ADAR1 expression and the underlying
mechanisms remain largely unclear.
The present study expands our knowledge of RNA
editing in thyroid cancer, the most common endocrine
malignancy with a steadily-rising incidence [17]. Analysis
of TCGA data [19] shows that A-to-I editing is significantly
elevated in thyroid tumors [13, 14], and ADAR1 expression
correlates with a worse progression-free survival [38]. We
confirm these data and describe for the first time, to our
knowledge, that ADAR1 editing activity has an important
role in thyroid cell tumorigenesis, as loss of ADAR1
function profoundly suppresses proliferation, invasion, and
Fig. 2 ADAR1 knockdown reduces thyroid cells invasion, migra-
tion in vitro and xenograft tumor growth in vivo. TPC1, Cal62, and
8505c cell lines were transfected with two different siRNAs against
ADAR1 (siADAR1 #1 and siADAR1 #2) or a control siRNA
(siControl). a Quantification of cell invasion. Upper panel: repre-
sentative images of the lower chamber (invading cells). Bottom panel:
cell invasion relative to siControl cells. b Quantification from a
wound-healing assay at the indicated time points after scratching. c, d
Xenograft tumors were generated by subcutaneous injection with
Cal62-Luc cells transfected previously with siControl (n= 8), siA-
DAR1 #1 (n= 7), or siADAR1 #2 (n= 7). c Endpoint (day 18) bio-
luminescent signal of the generated tumors. d Tumor radiance
quantification at the indicated time points. Values represent mean ± SD
(n= 3). ***p < 0.001 for the in vitro techniques (A and B), and mean
± SEM. */#p < 0.05; **/##p < 0.01 for the in vivo experiment (d).
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migration both in 2D and 3D cultures. The fact that the
same results were obtained in 3D cultures is encouraging as
these systems have proven to be more similar to the in vivo
environment. Patient-derived tumor cells grow in a 3D
conformation with a specific organization and architecture
that 2D monolayer cell culture cannot replicate, and it is
known that cells grown in a 3D model are physiologically
more relevant and better recapitulate some biological fea-
tures such as cell viability and proliferation [22].
In addition, we confirm the in vivo function of ADAR1 in
a mouse xenograft model. Thus, both the 3D in vitro and
in vivo systems are useful platforms for future studies to
screen for molecules, such as 8-aza, that inhibit ADAR1


























































































































































































































































































































Fig. 3 The ADAR1-dependent editing in miR-200b, increased in
thyroid cancer patients, decreasing its binding to ZEB1 3′UTR. a
Immunoblot for ADAR1 and ZEB1 72 and 92 h after TPC1 and
Cal62 siControl, siADAR1 #1 or siADAR1 #2 transfection. GAPDH
was used as a loading control. b Left: relative miR-200b edited (Edit)/
wild-type (WT) miRNA levels in six PTC patients (contralateral and
normal thyroid tissue). Right: total average of miR-200b Edit/WT
miRNA relative levels. c miR-200b Edit/WT miRNA relative levels in
TPC1 and Cal62 cells transfected with the siRNAs siControl, siA-
DAR1 #1 or siADAR1 #2. d Renilla luciferase reporter activity rela-
tive to Firefly luciferase was evaluated 72 h after transfection of ZEB1
3′UTR or the same construction with mutated predicted miR-200b-3p
binding sites (ZEB1 3′UTR miR-200b mut) in Cal62 cells co-
transfected with the siRNAs siControl, siADAR1 #1 or siADAR1 #2.
e Renilla luciferase reporter activity relative to Firefly luciferase was
evaluated 72 h after transfection of ZEB1 3′UTR or the same con-
struction with mutated predicted miR-200b-3p binding sites (ZEB1 3′
UTR miR-200b mut) in TPC1 and Cal62 cells co-transfected with the
WT miR-200b or edited (edit) miR-200b mimics or a negative
control (Neg.Control). Values represent mean ± SD (n= 3). *p < 0.05;
**p < 0.01; ***p < 0.001.
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thyroid tumor cells with 8-aza reduces cell viability, growth,
migration and invasion, and this effect occurs both in 2D
and 3D systems. The use of 8-aza as a treatment for thyroid
and other cancers is thus an attractive option. However,
practically, this is tempered by the finding that 8-aza has
significant hemodynamic effects and some adverse reac-
tions when given to rats [49] and, consequently, no data
exist on 8-aza treatment in animal cancer models. Never-
theless, our data propose RNA editing as a potential ther-
apeutic target for thyroid cancer and open the possibility to
design new molecules against ADAR1 activity with fewer
adverse effects but with good therapeutic potential.
Interestingly, our data point to ZEB1, a master EMT
transcription factor, as a key effector in the ADAR1 pathway
in thyroid tumorogenesis. While A-to-I activity is elevated in
thyroid cancer and other tumor types compared with normal
tissues, in others are low. This divergent activity or expression
of the editing enzymes in different tumors is not clearly
understood (reviewed in [15]), but might explain the dereg-
ulation of noncoding RNA editing in different tumor types,
which has been suggested to promote tumorigenesis. Because
miRNA function strongly depends on its sequence com-
plementarity with target genes, RNA editing can influence
regulatory functions by decreasing the effective amount of
WT miRNAs and generating novel miRNAs that inhibit a
different set of targets. For instance, increased ADAR-
mediated RNA editing of stem cell regulatory let-7 miRNAs
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siADAR1
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Fig. 4 Editing of miR-200b impairs its ability to inhibit ZEB1,
modulating the thyroid cell invasion capacity. a Left: representative
immunoblot for ADAR1 and ZEB1 72 h after transfection with WT
miR-200b or edited (edit) miR-200b mimics or negative control in
TPC1 and Cal62 cells. GAPDH was used as a loading control. Right:
quantification relative to the negative control transfected cells. b Cal62
cells were co-transfected with an siRNA (siControl or siADAR1) and
an miRNA mimic (negative control, WT miR-200b wt or edit miR-
200b mimics). Upper panel: representative images of the lower
chamber (invading cells). Bottom panel: quantification of invasion
relative to siControl—Neg. Control cells. Values represent mean ± SD
(n= 3). *p < 0.05; **p < 0.01; ***p < 0.001, ns nonsignificant.
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myeloid leukemia [39]. By contrast, decreased RNA editing
of miR-455-5p in melanoma allows for downregulation of
tumor suppressor CPEB1 and promotes tumor progression
[50]. In addition, ADAR1 is frequently downregulated in
metastatic melanoma, where it controls the expression of
~100 miRNAs that regulate genes related to melanoma phe-
notypes [51]. In the context of thyroid cancer, we focused on
an RNA-editing event in the seed region of the tumor sup-
pressor miR-200b, a key regulator of EMT and cancer
metastasis. miR-200b is one of the main regulators of ZEB1
and shows high levels of editing in TCGA PTC samples (n=
518) when compared with matched normal tissues (n= 69)
[38]. We confirmed this phenomenon by analyzing the edited
and WT miR-200b levels in six PTC patients, finding a sig-
nificant increase in the edited/WT ratio in tumor samples.
In addition, based on TCGA data, miR-200b editing
levels correlate with a worse progression-free survival [38].
We found that edited miR-200b exhibits a lower activity
against its target ZEB1-3′UTR in thyroid cancer cells,












































































































































































































































































Fig. 5 ADAR1 regulation in thyroid cancer. a Cal62 and TPC1 cells
were treated with DMSO (vehicle), 10 µM AKTi, 50 µM selumetinib
or the combination of both inhibitors. Left: representative immunoblot
for the indicated proteins. GAPDH was used as a loading control.
Right: ADAR1 p150 (upped panel) and ADAR1 p110 (bottom panel)
quantification relative to DMSO-treated cells. PCCl3-inducible HRAS
(b) or BRAF (c) cells were treated with doxycycline for 48 and 72 h.
Left panels: representative immunoblots. GAPDH was used as a
loading control. Right panels: ADAR1 p150 and ADAR1 p110 protein
level quantification relative to nontreated cells. Values represent mean
± SD (n= 3). *p < 0.05; **p < 0.01; ***p < 0.001, ns nonsignificant.
3746 J. Ramírez-Moya et al.
ADAR1-silenced cells. Moreover, the impaired ability of
edited miR-200b to inhibit ZEB1 could promote motility and
invasion by reducing the total amount of WT miR-200b in the
cell. Although we have focused our research on ZEB1 as a
main target of miR-200b, this miRNA is a critical regulator
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occur with other miR-200b targets—some of them crucial for
important processes such as angiogenesis, apoptosis, cell
cycle, invasion, metastasis, and chemosensitivity [52]. Our
data suggest that inhibition of miR-200b editing is an addi-
tional strategy to decrease cancer cell aggressiveness and
potentially resensitize cancer cells to chemotherapeutic
agents. miR-200b is downregulated in ATC but not in PTC.
Therefore, the mechanism of miR-200b inactivation in PTC is
not its downregulation, but rather a higher editing rate elicited
by ADAR1. By contrast, in ATC both processes could be
involved simultaneously.
Thyroid cancer comprises different entities that range
from differentiated tumors such as FTC and PTC to poorly
differentiated (PDTC) and fully undifferentiated (ATC)
tumors. It is well recognized that tumor suppressors and
oncogenes are involved in the evolution of thyroid carci-
nomas. BRAF and RAS, which exert their effects via the
differential activation of MAPK and/or PI3K signaling, are
the driver oncogenes in this tumor type. Using specific
kinase inhibitors, we show that ADAR1 regulation in
thyroid cancer cells is PI3K-dependent; however, the
simultaneous inhibition of both pathways promotes a more
robust repression of ADAR1 than PI3K inhibition alone.
Our data also indicate that the RAS oncogene, but likely not
BRAF, modulates ADAR1 activity. Consistent with these
data, the hyperactivation of signaling pathways in tumor-
igenesis as inducers of ADAR1 expression has been
reported in other systems, such as in leukemia stem cells
where JAK2 activates ADAR1 [39].
Our study shows that the regulation of the two isoforms
of ADAR1, p150 and p110, by PI3K is different, as the
activation of this pathway seems to increase the levels of
p150 but not p110. This suggests that the two isoforms
exhibit distinct functions and regulation, which could be
explained by the fact that cytoplasmic ADAR1 p150 is
interferon inducible whereas nuclear ADAR1 p110 is con-
stitutively expressed [7]. The specific roles of these iso-
forms are unknown at present and future studies are needed
to understand the role of each of these isoforms in thyroid
cancer. Curiously, it has been described that the interaction
between ADAR1 p150 and DICER in viral myocarditis
promotes the expression of specific miRNAs [53]. As we
have previously demonstrated the important role of miR-
146b in thyroid cancer as an oncogenic miRNA that inhibits
PTEN [10] and DICER1 [54], the aforementioned interac-
tion could be tested in our system to question whether the
ADAR1-DICER1 complex promotes the activity of this
miRNA in thyroid cancer.
In summary, ADAR1 activation in cancer is a novel
mechanism of tumorigenesis that merits continued in-depth
study. ADAR1 has also been proposed as a new target for
immune-oncology therapy, and it has recently been reported
that silencing ADAR1 could make tumor cells more susceptible
to immunotherapy [48, 55, 56]. Our novel data establish for the
first time the significant role of ADAR1-dependent editing in
thyroid cancer, and provide insight into the mechanism of
action of this process in thyroid tumorigenesis by unveiling
miR-200b editing as responsible, at least in part, for the
aggressive features induced by ADAR1. Finally, our results
underscore RNA editing inhibition as a viable option for the
treatment of advanced thyroid cancer.
Materials and methods
Patients
Samples of PTC tumors and contralateral normal thyroid tissue
from the same patients (n= 6) were collected at the Biobank of
the La Paz University Hospital (Madrid, Spain). The main
clinical characteristics of the patients are summarized in Table
S1. Informed consent was obtained from all the patients fol-
lowing the protocols approved by hospital ethics committee.
Cell culture
The thyroid cell lines TPC1, Cal62, and 8505c were grown
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS). The sources of
the cell lines have been described [57]. PCCl3-BRAF and
PCCl3-HRAS were derived from PCCl3 rat thyroid folli-
cular cells [58], to obtain doxycycline-inducible expression
of BRAFV600E or HRASV12 [57, 59, 60]. All cell lines used
in this work were tested for mycoplasma contamination and
authenticated every 6 months by short tandem repeat pro-
files using the Applied Biosystems Identifier kit in the
Genomic Facility at the Institute of Biomedical Research
(IIBm; Madrid, Spain).
Transfections
siRNAs and miRNA mimics were transfected using Lipo-
fectamine RNAimax (Thermo Fisher). Luciferase assays
were performed using Lipofectamine 2000 (Thermo Fisher).
OptiMEM was used as a reduced serum medium in all
transfections.
Fig. 6 Inhibition of RNA A-to-I editing reduces viability and
proliferation of thyroid cancer cells. TPC1 and Cal62 cells were
treated with 8-azaadenosine (8-aza) (1 µM or 2 µM) or water
(H20). a Relative AZIN1 edited/AZIN1 wild-type (AZIN1 Edit/WT)
mRNA levels assayed by RESS-qRT-PCR 72 h post treatment. b
Relative ADAR1 mRNA level assayed by qRT-PCR 72 h post treat-
ment. c MTT assays at the indicated time points at 100 nM, 500 nM,
1 µM, and 2 µM 8-aza concentration. d Upper panel: representative
images of crystal violet-stained cells. Bottom panel: quantification
relative to nontreated cells. Values represent mean ± SD (n= 3). *p <
0.05; **p < 0.01; ***p < 0.001.
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siRNAs, mimics, and plasmids
The siRNAs were purchased from Thermo Fisher (siControl
[Silencer Select Negative Control #1 4390843] siADAR1
#1 [4390824] and siADAR1 #2 [AM5133]). miR-200b-3p
mimics for the WT (C-300582-07-0002 miRIDIAN
miRNA) and the edited form (mature sequence: UAAUG-
CUGCCUGGUAAUGAUGA) and the negative control
(miRIDIAN miRNA Mimic Negative Control #1) were
purchased from Cultek. In addition, the following vectors
were obtained from Addgene: pCI-neo-RL-ZEB1 (Addgene
plasmid #35535) and pCI-neo-RL-ZEB1 200bmut × 5
(Addgene plasmid #35537) [30], and were gifts from Greg
Goodall (University of South Australia). A vector expres-
sing luciferase and GFP, CMV-Firefly Luc-IRES-EGFP,



















































































































Fig. 7 Inhibition of RNA A-to-I editing reduces 3D growth and 2D
invasion and migration in thyroid cancer cells. TPC1 and Cal62 cell
lines were treated with 8-azaadenosine (8-aza) (1 or 2 µM) or water
(H2O). a 3D cell culture in Matrigel. b Upper panel: representative
images of the lower chamber (invading cells). Bottom panel: cell
invasion relative to the nontreated cells. c Quantification from a
wound-healing assay at the indicated time points after scratching.
Values represent mean ± SD (n= 3). *p < 0.05; **p < 0.01; ***p <
0.001.
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human tumoral thyroid cells stably expressing the vector
(Cal62-Luc) were generated by Dr Eugenia Mato (IIB,
Sant Pau).
RNA quantification
Total RNA was isolated from cells with Trizol Reagent
(Invitrogen). Reverse transcription-PCR (RT-PCR) assays
for coding genes was performed using the M-MLV Reverse
Transcriptase Kit (Promega Corporation). Quantitative RT-
PCR (qRT-PCR) was performed with Kapa Sybr Fast
Universal Kit from Sigma-Aldrich. All primers were pur-
chased from Sigma-Aldrich and are described in Table S2.
RNA editing quantification
To quantify RNA editing activity, we analyzed the pre-
viously described editing site in the AZIN1 transcript. We
used the RNA editing site-specific primer design strategy
that is compatible with SYBR green qRT-PCR protocols
(RESSq-PCR), as described [61]. Briefly, one pair of
RESSq-PCR primers detects the WT transcript (an “A”
base), and the other pair detects the edited transcript con-
taining a “G” base, representing the inosine substitution.
To enhance allelic discrimination, the primers differ in the
3’ nucleotide position to detect the WT A or the edited G
nucleotide, and an additional mismatch was incorporated
two nucleotides upstream of the 3′ primer end. Both pairs
of primers are described in Table S2. For miR-200b WT
(UAAUACUGCCUGGUAAUGAUGA) and edited var-
iant (UAAUGCUGCCUGGU AAUGAUGA) recognition,
miRNAs were retrotranscribed using the miRCURY™
LNA™ Universal RT miRNA PCR Kit, and qRT-PCR was
performed using the miRCURY LNA SYBR® Green PCR
Kit (Qiagen) with specific commercial primers for WT
miR-200b WT and edited miR-200b, optimized with
LNA technology to enable sensitive and specific miRNA
quantification.
Protein extraction, western blotting, and antibodies
Cells were lysed and proteins extracted with RIPA buffer
[10, 54]. Protein concentration was measured using the
Bradford method (Bio-Rad Laboratories). Samples were
separated by SDS-PAGE and transferred to nitrocellulose
membranes (Bio-Rad Laboratories). The following antibodies
were obtained from Santa Cruz Biotechnology Inc.: ADAR1
(SC-73408), p-AKT ser473 (sc-7985-R), AKT
(sc-8312), pERK Tyr204 (sc-7383), and HRAS (C-20) (sc-
520). ERK1/2 (#9102) and ZEB1 (#3396) antibodies were
purchased from Cell Signaling Technology Inc., the PCNA
(ab92552) antibody was from Abcam and the GAPDH
(MAB374) antibody was from EMD Millipore Corp.
MTT assay and crystal violet-stained colonies
Thiazolyl blue tetrazolium bromide (MTT) assays were
performed using a kit from Sigma-Aldrich (M2128-
500MG). Cells were seeded in 96-well plates (1000 and
2000 cells/well for Cal62 and 8505c cell lines or 500 and
1000 cells/well for the TPC1 cell line) and measurements
were carried out in a spectrophotometer. To assay cell
viability by crystal violet staining, 2500 Cal62 or 8505c
cells, or 1500 TPC1 cells were seeded in each well of a six-
well plate 24–48 h after transfection. Individual wells were
fixed in 4% formaldehyde after 7–10 days and stained with
crystal violet. After extensive washing and drying, crystal
violet was resolubilized in 1% acetic acid and quantified at
600 nm as an indirect measure of cell number.
Three-dimensional cell growth
A total of 5000 Cal62 or TPC1 cells were resuspended in
DMEM containing 5% Matrigel (Matrigel® Growth Factor
Reduced Basement Membrane Matrix [LDEV-free] from
Corning, and were seeded on the top of a 24-well plate
containing 500 μL of Matrigel, which was added 30 min
before seeding. The medium was replaced every 3–4 days.
Invasion and migration assays
Cell invasion was examined in Transwell cell culture
chamber filters coated on the upper side with Matrigel
(Corning Biocoat) as described [54]. Cells were seeded at
5 × 104 for Cal62 and 8505c cells and 3 × 104 for TPC1 cells
in DMEM culture medium with 0.2% FBS 48 h after
transfection. Wound-healing assays were performed as
described [54], 48 h after transfection.
In vivo study
Animal experimentation was performed in compliance
with the European Community Law (86/609/EEC) and
the Spanish law (R.D. 1201/2005), with the approval of
the ethics committee of the Consejo Superior de Inves-
tigaciones Científicas (CSIC, Spain). Xenotransplants
were established in 6-week-old female BALB/c nude (nu/
nu) mice by subcutaneous injection in the left flank of
1 × 106 Cal62-luc cells previously transfected with the
corresponding siRNA and suspended in 50 μl of PBS
mixed with 50 μl of Matrigel. Mice were randomly
divided in three groups and xenografts were established
in 22 animals. Tumor bioluminescent signals were
determined in vivo at the indicated time points to cal-
culate tumor growth, as described [10], and mice were
imaged with the IVIS-Lumina II Imaging System (Cali-
per Life Sciences).
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Luciferase assay
To measure the reporter, Renilla luciferase, activity of the
ZEB1 3′UTR, the pCI-neo-RL-ZEB1 vector (ZEB1 3′UTR)
or the pCI-neo-RL-ZEB1 200bmutx5 vector, containing
mutations in the miR-200b-3p binding sites (ZEB1 3′UTR
miR-200b-mut) was transfected together with a control
Firefly luciferase plasmid and the corresponding siRNA or
mimic. At 48 h after transfection, cells were harvested and
assayed with the Dual-Luciferase Reporter Assay Kit
(Promega Corporation). Renilla luciferase activity was
normalized to firefly luciferase activity.
Cell treatments with AKTi, selumetinib, and 8-
azaadenosine
Cells were treated with AKTi (Tocris), selumetinib (LC
Laboratories), or a combination of both drugs for 24 h to final
concentrations of 10 and 50 µM, respectively. Both drugs were
dissolved in DMSO. 8-azaadenosine (8-aza) (AKOS03053
0872, Akos Consulting & Solutions GmbH) was used to
inhibit RNA editing. 8-aza dissolved in water was added to the
cell culture medium at the indicated final concentrations.
Statistical analysis
Results are expressed as the mean ± SD of at least three
different experiments performed in triplicate. Results from
the in vivo studies and patient analysis are expressed as the
mean ± SEM. Statistical significance was determined by
Student’s t test analysis (two tailed) and differences were
considered significant at a P value < 0.05.
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